Metoprolol and Formoterol in Chronic Obstructive Pulmonary Disease (COPD)

Martini Hospital Groningen

Status and phase

Unknown

Phase 4

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Treatments

Drug: Metoprolol

Study type

Interventional

Funder types

Other

Identifiers

NCT00288548

MeFCo2

Details and patient eligibility

About

We want to study the effect of the combination of metoprolol (a beta-blocker) with formoterol (a beta-agonist) on long function in patients with Chronic Obstructive Pulmonary Disease (COPD). There are more and more clues that a beta-blocker, when well chosen and in the right dosage, won't harm the long function in patients with COPD. Since a beta-blocker can be a valuable addition to treating patients with heart problems we would like to see if this category of medication can be available for COPD patients in the future.

Sex

All

Ages

40 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

male/female aged between 40-70 inclusive
COPD defined by GOLD criteria
FEV1 greater or equal to 60% of predicted without medication
baseline FEV1 greater or equal than 1.2L
10 or more pack years
no hard contraindications for use of beta blockers
being able to perform technically acceptable pulmonary function tests
signed informed consent
systolic blood pressure equal to 130 or greater

Exclusion criteria

instable COPD during the month before visit 1
usage of corticosteroids during the month before visit 1
significant pulmonary diseases other than COPD
a history of cancer within the last 5 years (basal cell carcinoma or cutaneous squamous cell carcinoma allowed)
a recent history of myocardial infarction
use of an investigational drug within one month or six half lives (which ever is greater) of visit 1
contra-indications for the use of ipratropium-bromide